Trending...
- Naperville Police Host College Safety Webinar for Students and Parents on July 31
- Open Appeal: Renew Indian Passports by Citizenship, Not Immigration Status
- AF 5.0: Why AF5.0 Is Becoming a Core Platform for Quantitative Education
~ A new study has found that once-weekly insulin efsitora alfa (efsitora) is just as effective as daily basal insulin in lowering blood glucose levels in people with type 2 diabetes. The results of the QWINT-1 study were presented at the 85th Scientific Sessions of the American Diabetes Association® (ADA) in Chicago and published simultaneously in The New England Journal of Medicine.
The study, which was the first of its kind, aimed to address the growing need for simpler options for insulin therapy. According to the findings, one in four people with type 2 diabetes do not take their prescribed dosage of basal insulin correctly due to the burden of daily injections and frequent dose adjustments. This can lead to dangerous high blood glucose levels and long-term organ damage.
QWINT-1 was a Phase 3, open-label, randomized study that evaluated the efficacy and safety of a fixed-dose titration of once-weekly insulin efsitora in 795 adults with type 2 diabetes who were taking basal insulin for the first time. The study compared efsitora to once-daily insulin glargine, with the goal of determining whether a fixed-dose, once-weekly regimen could offer comparable blood glucose management while reducing the burden of starting and managing insulin therapy. Efsitora was titrated to four fixed doses at four-week intervals as needed for blood glucose management.
More on illi News
After 52 weeks, the study showed that efsitora lowered A1C levels by 1.31%, reaching an average A1C of 6.92%, compared to a reduction of 1.27% and an A1C of 6.96% with insulin glargine. A second analysis based on how well patients followed their treatment also showed similar results: efsitora reduced A1C by 1.19% (to 7.05%) compared to a reduction of 1.16% (to 7.08%) with glargine.
Lead investigator of the QWINT-1 trial, Dr. Julio Rosenstock, senior scientific advisor at Medical City Dallas and clinical professor of medicine at the University of Texas Southwestern Medical Center, stated that these results confirm the effectiveness of once-weekly insulin efsitora in controlling blood sugar levels while also offering the benefit of a simpler dosing schedule. He also noted that the novel fixed-dose regimen used in the study has the potential to ease the burden of starting insulin therapy for both patients and providers, potentially improving adherence and long-term health outcomes.
More on illi News
In light of these findings, Lilly has announced plans to submit efsitora for the treatment of type 2 diabetes to global regulatory authorities by the end of 2025.
The results of this study were presented by Dr. Rosenstock at a symposium titled "Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!" on Sunday, June 22 at 2:20 p.m. CT. The presentation focused on the efficacy and safety of efsitora as a weekly basal insulin using a novel fixed-dose escalation compared to insulin glargine in insulin-naïve participants with type 2 diabetes.
This groundbreaking study offers hope for people with type 2 diabetes who struggle with daily injections and dose adjustments for basal insulin therapy. With once-weekly insulin efsitora showing comparable results to daily basal insulin, it has the potential to simplify treatment and improve long-term health outcomes for patients.
The study, which was the first of its kind, aimed to address the growing need for simpler options for insulin therapy. According to the findings, one in four people with type 2 diabetes do not take their prescribed dosage of basal insulin correctly due to the burden of daily injections and frequent dose adjustments. This can lead to dangerous high blood glucose levels and long-term organ damage.
QWINT-1 was a Phase 3, open-label, randomized study that evaluated the efficacy and safety of a fixed-dose titration of once-weekly insulin efsitora in 795 adults with type 2 diabetes who were taking basal insulin for the first time. The study compared efsitora to once-daily insulin glargine, with the goal of determining whether a fixed-dose, once-weekly regimen could offer comparable blood glucose management while reducing the burden of starting and managing insulin therapy. Efsitora was titrated to four fixed doses at four-week intervals as needed for blood glucose management.
More on illi News
- Bent Danholm To Be Featured On Global Podcast Network In Live Interview
- AdvoCast Expands Leadership in Strategic Comms with New Role Producing "Communication Breakdown" Podcast
- InventHelp Inventor Develops Wearable Tracking Device (CHK-2215)
- Naperville: Structure Fire in the 1000 Block of Frances Court
- Rocket.Chat assessed "Awardable" for Department of Defense work in the CDAO's Tradewinds Solutions Marketplace
After 52 weeks, the study showed that efsitora lowered A1C levels by 1.31%, reaching an average A1C of 6.92%, compared to a reduction of 1.27% and an A1C of 6.96% with insulin glargine. A second analysis based on how well patients followed their treatment also showed similar results: efsitora reduced A1C by 1.19% (to 7.05%) compared to a reduction of 1.16% (to 7.08%) with glargine.
Lead investigator of the QWINT-1 trial, Dr. Julio Rosenstock, senior scientific advisor at Medical City Dallas and clinical professor of medicine at the University of Texas Southwestern Medical Center, stated that these results confirm the effectiveness of once-weekly insulin efsitora in controlling blood sugar levels while also offering the benefit of a simpler dosing schedule. He also noted that the novel fixed-dose regimen used in the study has the potential to ease the burden of starting insulin therapy for both patients and providers, potentially improving adherence and long-term health outcomes.
More on illi News
- Suburban Orthopaedics Expands Foot and Ankle Team with Fellowship-Trained Surgeon Shoueb Malik, DPM
- Rising Home Values Aren't Preventing Foreclosures
- Success for Global Communications Leader IQSTEL, Inc. Growing From $13 Million Revenue in 2018 to Nearly $300 Million Last Year
- Designer Creates 100 Free Posters for Black Business Month
- Artbound: "The Cheech" Awarded Two 2025 LA Area EMMY Awards — Honored in ARTS & MUSIC COMPOSITION
In light of these findings, Lilly has announced plans to submit efsitora for the treatment of type 2 diabetes to global regulatory authorities by the end of 2025.
The results of this study were presented by Dr. Rosenstock at a symposium titled "Advancing and Facilitating Basal Insulin Therapy in Type 2 Diabetes—Breaking News on the QWINT 1, 3, and 4 Trials with Once-Weekly Insulin Efsitora Alfa!" on Sunday, June 22 at 2:20 p.m. CT. The presentation focused on the efficacy and safety of efsitora as a weekly basal insulin using a novel fixed-dose escalation compared to insulin glargine in insulin-naïve participants with type 2 diabetes.
This groundbreaking study offers hope for people with type 2 diabetes who struggle with daily injections and dose adjustments for basal insulin therapy. With once-weekly insulin efsitora showing comparable results to daily basal insulin, it has the potential to simplify treatment and improve long-term health outcomes for patients.
Filed Under: Business
0 Comments
Latest on illi News
- Private Autopsies Provide Families in Colorado with Answers and Closure
- Vijay Tirathrai named Managing Director in Dubai, UAE
- How smart women use BAY Miner cloud mining to easily earn Bitcoin every day
- Qualis LLC Appoints Jeremy Mallicoat as Chief Financial Officer to Advance Growth and Acquisition Strategy
- Bynn Intelligence Reinvents Document Fraud Detection with Groundbreaking Acquisition and Revolutionary AI Model
- Mentor Agile Says WIOA‑Funded Seats Still Available for Summer Product‑Owner
- 2A Commerce Launches Firearms eCommerce Platform
- GOAT SKIN® Launches the Campaign Tee: A Sovereign Statement in Luxury Apparel
- Midwest Pond Features & Landscape Says "We're Ready for Repairs"
- Brianne Zitko Named Winner of 2025 Great Companies International Women Entrepreneur Award
- 4Closure Rescue Expands Foreclosure Support Services to Underserved Communities Across the U.S
- Premier Protein® and Milk Bar® Launch New "Power Hour" Protein Menu
- Exposing Psychiatric Abuse, CCHR Has Pushed for Global Human Rights Protections
- Spur Chicago Builds Momentum Through Summer Field Collaborations
- RDG Mining launches 1-day XRP、BTC mining contract, XRP short-term investment users surge 500%
- Donna Cardellino and Paul Lafrance Sign Exclusive Deal for Worldwide Expansion into Commercial and Luxury Real Estate Design Projects
- New Book "Three Permissions" Redefines Self-Leadership for a Burnout-Weary Culture
- Opening a new era of USDC smart cloud mining: CJB Crypto makes digital dollar earnings within reach
- The Evolution of the BDCV Platform: Empowering Mental Health & Wellness
- DFS Fullcolor Printing by Inkdnylon | Nationwide Print Partner